Cost-utility analysis using a Markov decision model finds that platelet-rich plasma (PRP) is not cost-effective in rotator cuff repair because of no added outcomes benefit or improvement in retear rate according to best current evidence (Level I to III studies). To achieve the willingness-to-pay threshold, PRP would need to reduce rotator cuff retear rates. The authors have opened dialogue for us to determine what is the value and what should be the cost for PRP when it comes to rotator cuff repair.
|Original language||English (US)|
|Number of pages||2|
|Journal||Arthroscopy - Journal of Arthroscopic and Related Surgery|
|State||Published - Jul 1 2016|
ASJC Scopus subject areas
- Orthopedics and Sports Medicine